PDCD1 and neoplasm: In the hPD-1 KI mouse, GNUV201 significantly inhibited MC38 tumor growth (55.9% TGI, P < 0.0001); its anti-tumor effect is comparable to that of Keytruda® and Opdivo® (Keytruda®: 57.4% TGI, P < 0.0001, Opdivo®: 63.9% TGI, P < 0.0001, GNUV201 vs Keytruda® and Opdivo®, P > 0.4) (Fig. 5d).